StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a note issued to investors on Sunday. The firm set a “hold” rating on the stock.
NYSE:OGEN opened at $0.33 on Friday. The firm has a market cap of $38.42 million, a PE ratio of -2.36 and a beta of 0.12. The business’s 50 day moving average price is $0.33. Oragenics has a 1-year low of $0.22 and a 1-year high of $1.15.
Oragenics (NYSE:OGEN – Get Rating) last announced its quarterly earnings data on Thursday, March 24th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.09 million during the quarter.
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Stories
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
